z-logo
open-access-imgOpen Access
Potential therapeutic role of cisplatinum in autologous bone marrow transplantation: in vitro eradication of neuroblastoma cells from bone marrow
Author(s) -
Laurence BettanRenaud,
Florent de Vathaire,
Jean Bénard,
N Morardet,
N Pauzie,
S. Bayet,
Olivier Hartmann,
C Parmentier
Publication year - 1989
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/bjc.1989.307
Subject(s) - neuroblastoma , bone marrow , transplantation , progenitor cell , cancer research , medicine , human bone , therapeutic index , in vitro , pathology , cell culture , biology , stem cell , pharmacology , biochemistry , genetics , drug
Cisplatinum may prove to be a valuable agent for the elimination of diseased cells in the bone marrow of patients with neuroblastoma. In this study, we measured the efficacy of cisplatinum on human neuroblastoma cell lines and on normal human bone marrow progenitors, GM-CFC and CFU-F. Data indicate that the therapeutic index of cisplatinum is high. We set up an experimental model consisting of a mixture of human bone marrow and human neuroblastoma cells in order to confirm these preliminary results in purging conditions. Results indicate that cisplatinum exhibits a high and specific tumoricidal property and appears to be valid in bone marrow purging.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom